New Immunocapture Enzyme (ICE) Assay for Quantification of Cancer Procoagulant Activity: Studies of Inhibitors

Summary

A new, sensitive and specific immunocapture enzyme (ICE) assay for quantitation of the enzymatic activity of cancer procoagulant (CP) has been developed. The assay had good reproducibility (inter- and intra-assay CV were 6.4% and 5.7% respectively) and was linear for concentrations of CP from 0.5 μg/ml to 10 μg/ml (r² = 0.995). Using this assay the inhibition of CP by iodoacetamide, mercuric chloride, E-64, leupcptin and antipain was demonstrated. There was no significant effect of cystatin and natural plasma proteinase inhibitors α₁-antitrypsin, α₁-antichymotrypsin, α₂-macroglobulin and antithrombin-III/heparin, on the activity of the CP.

• References

• 1 Gordon SG, Cross BA. A factor X-activating cysteine proteinase from malignant tissue. J Clin Invest 1981; 67: 1665-71
• 2 Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985; 24: 5558-67
• 3 Gordon SG, Hasiba U, Cross BA, Poole MA, Falanga A. A cysteine proteinase procoagulant from amnion-chorion. Blood 1985; 66: 1261-5
• 4 Falanga A, Shaw E, Donati MB, Consonni R, Barbui T, Gordon SG. Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium salts. Thromb Res 1989; 54: 389-98
• 5 Moore WR. The purification and properties of cancer procoagulant from murine tumors. Biochem Biophys Res Com 1992; 184: 819-24
• 6 Mielicki WP, Gordon SG. Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant. Blood Coag Fibrinol 1993; 4: 441-6
• 7 Gordon SG, Cross BA. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. Cancer Res 1990; 50: 6259-64
• 8 Gordon SG. Cancer cell procoagulants and their role in malignant disease. Seminars Tkumb Haemost 1992; 18: 424-33
• 9 Edwards RL, Silver J, Rickies FR. Human tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haemostas 1993; 69: 205-13
• 10 Gordon SG, Benson B. Analysis of serum cancer procoagulant activity and its possible use as a tumor marker. Thromb Res 1989; 56: 431-40
• 11 Falanga A, Consonni R, Marchetti M, Mielicki WP, Rambaldi A, Lanotte M, Gordon SG, Barbui T. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by alltrans retinoic acid. Leukemia 1994; 8: 156-9
• 12 Suda H, Aoyagi T, Hamada M, Takeuchi T, Umezawa H. Antipain, a new protease inhibitor isolated from actinomycetes'. J Antibiotics 1972; 25: 263-6
• 13 Umezawa H. Structures and activities of protease inhibitors of microbial origin. Methods in Enzymology 1976; 45: 678-85
• 14 Gordon SG, Mourad AM. The site of activation of factor X by cancer procoagulant. Blood Coag Fibrinol 1991; 2: 735-9
• 15 Mielicki WP, Wierzbicki R. Cancer procoagulant in serum of rats during development of experimental epithelioma. Int J Cancer 1990; 45: 125-6
• 16 Barrett AJ. α₂-Macroglobulin. Methods in Enzymology 1981; 80: 737-54
• 17 Barrett AJ. Cystatin, the egg white inhibitor of cysteine proteinases. Methods in Enzymology 1981; 80: 771-8